AC
ENGNW icon

Aristeia Capital’s enGene Therapeutics Warrants ENGNW Stock Holding History

Aristeia Capital’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$445K Buy
+164,511
New +$487K 0.01% 395
2024
Q1 		– Sell
-24,045
Closed -$28.3K – 300
2023
Q4 		$28.3K Buy
+24,045
New +$18.5K ﹤0.01% 128

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Aristeia Capital's ENGNW Position: Q1 2026 in Review

Aristeia Capital opened a new position in enGene Therapeutics Warrants (ENGNW) in Q1 2026: 164,511 shares worth $445K. The stake represents 0.01% of the portfolio and ranks #395 among its holdings. This is a return to the name: Aristeia Capital previously reported a position in ENGNW as recently as Q4 2023.

Aristeia Capital first reported a position in ENGNW in Q4 2023 and has held it in 2 quarters since. 11 funds tracked by Wall St. Rank hold ENGNW as of Q1 2026.

  • Aristeia Capital held 164,511 shares of enGene Therapeutics Warrants worth $445K as of Q1 2026.
  • enGene Therapeutics Warrants was a new Aristeia Capital position in Q1 2026.
  • enGene Therapeutics Warrants made up 0.01% of Aristeia Capital's portfolio in Q1 2026, its #395 holding.
  • Aristeia Capital first reported a position in enGene Therapeutics Warrants in Q4 2023 and has held it in 2 quarters since.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q1 2026.

Based on Aristeia Capital's 13F filing for Q1 2026, filed 15 May 2026.